Puttur: Several injured in clash between SKSSF and SSF activists

[email protected] (CD Network)
February 18, 2014

Puttur, Feb 18: The intermittent group clashes between two Sunni students' groups spilt over to Puttur with both organisations accusing members of the other of assaulting them at a masjid in Kedila village, Puttur taluk.

Three of the injured have been identified as Sahul Hameed (29), Shimshar (18) and Shabeed (18). They are undergoing treatment at a private hospital at Puttur.

The incident was reported near the Galimukha mosque on February 16, Sunday.

Around 7.30 p.m., members of the Sunni Students' Federation (SSF) and Samastha Kerala Sunni Students Federation (SKSSF) got into a fist fight in the premises of the BTA Masjid, said the Puttur Town Police.

Both groups have lodged cases against each other. Several SKSSF workers were also injured and are admitted to different hospitals.

The tension stems from an SKSSF conference a week ago in Sullia, where a speaker had alleged that SSF had misappropriated Rs. 40 crore in collections.

SSF

Comments

Dortha Christmas
 - 
Tuesday, 24 May 2016

Invaluable discussion for what it is worth, if anyone is wanting to merge two PDF files, we stumbled across article

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
coastaldigest.com web desk
July 1,2020

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 10,2020

Mangaluru, Jan 10: A person has been booked for forwarding provocative message on WhatsApp against the Dakshina Kannada Khazi Twaqa Ahmed Musliyar.

According to police, the accused Hassan forwarded provocative messages against the Khazi in a WhatsApp group on December 31, following which he was booked under several sections of Indian Penal Code (IPC).

Mangalore North Police are looking into the matter. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 9,2020

Bengaluru, Jun 9: A 24-year-old who wanted to experience the feeling of death lost his life after consuming pesticide — he recorded it all on TikTok — in Koratagere taluk of Tumakuru district on Saturday evening.

Chided by his mother for not earning money, Dhananjaya, a resident of Gouraganahalli, on Saturday evening bought pesticide from a shop and shot a 15-second TikTok video, saying, “I want to experience the feeling of what death would be like. I will try to kill myself.”

Locals rushed Dhananjaya to a nearby hospital where he breathed his last the next morning. Koratagere police registered a case of unnatural death.

According to police, Dhananjaya had in the past rammed his Bajaj Pulsar bike into a tree to ‘experience’ death but had survived with minor injuries. Villagers and family members had advised him to not to take such risks. But he continued to do so as he was obsessed with death and posted his opinion regularly on TikTok, where he had 431 followers.

He tied the knot four months ago and was running an autorickshaw on rent. However, his earnings reduced to zero during the lockdown and he wasn’t mentally stable, claimed villagers.

Investigators said Dhananjaya wanted to scare his mother with his suicide threat and wanted to ‘experience’ death. He consumed poison near a farm but later panicked thinking he would die. However, he was not in a position to ride back home. He called his friend, who visited the spot and shifted him to hospital on Saturday night, police said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.